bupivacaine has been researched along with Colorectal Neoplasms in 12 studies
Bupivacaine: A widely used local anesthetic agent.
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.
bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our objective is to investigate the efficacy and safety of intraperitoneal dexmedetomidine (Dex) combined with bupivacaine in patients undergoing laparoscopic colorectal cancer surgery." | 9.20 | Efficacy and safety of intraperitoneal dexmedetomidine with bupivacaine in laparoscopic colorectal cancer surgery, a randomized trial. ( Abd El-Rahman, AM; Amin, AT; Fares, KM; Mohamed, AA; Mohamed, SA, 2015) |
| "To probe into the impact of Bupivacaine on colorectal cancer (CRC) proliferation, apoptosis, and autophagy through regulating the NF-κB signaling pathway." | 8.02 | Impact of Bupivacaine on malignant proliferation, apoptosis and autophagy of human colorectal cancer SW480 cells through regulating NF-κB signaling path. ( Hou, Z; Liu, B; Yan, X; Zhang, D; Zhang, L, 2021) |
| "Our objective is to investigate the efficacy and safety of intraperitoneal dexmedetomidine (Dex) combined with bupivacaine in patients undergoing laparoscopic colorectal cancer surgery." | 5.20 | Efficacy and safety of intraperitoneal dexmedetomidine with bupivacaine in laparoscopic colorectal cancer surgery, a randomized trial. ( Abd El-Rahman, AM; Amin, AT; Fares, KM; Mohamed, AA; Mohamed, SA, 2015) |
| "To probe into the impact of Bupivacaine on colorectal cancer (CRC) proliferation, apoptosis, and autophagy through regulating the NF-κB signaling pathway." | 4.02 | Impact of Bupivacaine on malignant proliferation, apoptosis and autophagy of human colorectal cancer SW480 cells through regulating NF-κB signaling path. ( Hou, Z; Liu, B; Yan, X; Zhang, D; Zhang, L, 2021) |
| "Risk of pneumonia was reduced after EA (odds ratio (OR), 0." | 1.37 | Epidural analgesia in open resection of colorectal cancer: is there a clinical benefit? a retrospective study on 1,470 patients. ( Beutner, U; Filipovic, M; Lüthi, A; Müller, SA; Schmied, BM; Steffen, T; Tarantino, I; Warschkow, R, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chevrollier, GS | 1 |
| Klinger, AL | 1 |
| Green, HJ | 1 |
| Gastanaduy, MM | 1 |
| Johnston, WF | 1 |
| Vargas, HD | 1 |
| Kann, BR | 1 |
| Whitlow, CB | 1 |
| Paruch, JL | 1 |
| Byrnes, KG | 1 |
| Sahebally, SM | 1 |
| Burke, JP | 1 |
| Kalu, R | 1 |
| Boateng, P | 1 |
| Carrier, L | 1 |
| Garzon, J | 1 |
| Tang, A | 1 |
| Reickert, C | 1 |
| Stefanou, A | 1 |
| Liu, B | 1 |
| Yan, X | 1 |
| Hou, Z | 1 |
| Zhang, L | 1 |
| Zhang, D | 1 |
| Fares, KM | 1 |
| Mohamed, SA | 1 |
| Abd El-Rahman, AM | 1 |
| Mohamed, AA | 1 |
| Amin, AT | 1 |
| Oh, TK | 1 |
| Yim, J | 1 |
| Kim, J | 1 |
| Eom, W | 1 |
| Lee, SA | 1 |
| Park, SC | 1 |
| Oh, JH | 1 |
| Park, JW | 1 |
| Park, B | 1 |
| Kim, DH | 1 |
| Warschkow, R | 1 |
| Steffen, T | 1 |
| Lüthi, A | 1 |
| Filipovic, M | 1 |
| Beutner, U | 1 |
| Schmied, BM | 1 |
| Müller, SA | 1 |
| Tarantino, I | 1 |
| Lattermann, R | 2 |
| Carli, F | 2 |
| Wykes, L | 2 |
| Schricker, T | 2 |
| Meterissian, S | 1 |
| Eberhart, L | 1 |
| Müller, M | 1 |
| Schück, R | 1 |
| Erkens, U | 1 |
| Sticher, J | 1 |
| Haase, C | 1 |
| Hempelmann, G | 1 |
| Sala, C | 1 |
| García-Granero, E | 1 |
| Molina, MJ | 1 |
| García, JV | 1 |
| Lledo, S | 1 |
| Riwar, A | 1 |
| Schär, B | 1 |
| Grötzinger, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TAP (Transverse Abdominis Plane) Block With Exparel (Liposomal Bupivicaine) vs. Bupivicaine Post-op Pain Management[NCT04781075] | Phase 4 | 76 participants (Actual) | Interventional | 2017-12-01 | Completed | ||
| Randomized Prospective Study Comparison of Erector Spinae Plane Block and Intrathecal Opioid for Postoperative Analgesia After Laparoscopic Colorectal Surgery in an Enhanced Recovery Setting[NCT05257941] | Phase 1/Phase 2 | 126 participants (Anticipated) | Interventional | 2022-01-27 | Recruiting | ||
| TAP Blocks Performed With Bupivacaine Versus Liposomal Bupivacaine in Colorectal Surgery Patients: A Prospective, Cluster Randomized Trial[NCT03638635] | Phase 4 | 63 participants (Actual) | Interventional | 2018-05-14 | Terminated (stopped due to Lack of personnel available to complete study.) | ||
| Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia[NCT02032953] | Phase 4 | 24 participants (Anticipated) | Interventional | 2013-12-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Amount of ondansetron patient required postoperatively during hospital stay, in milligrams (NCT03638635)
Timeframe: Time of transfer to post operative suite to time of discharge (usually up to 4 days after surgery).
| Intervention | mg (Mean) |
|---|---|
| Standard Bupivacaine | 2.9 |
| Bupivacaine Liposome | 5.6 |
Total postoperative hospital stay in days (NCT03638635)
Timeframe: Date of surgery to date of discharge (usually up to 4 days after surgery).
| Intervention | days (Median) |
|---|---|
| Standard Bupivacaine | 3 |
| Bupivacaine Liposome | 3.5 |
Recorded on a scale of 0 (No pain) to 10 (Worst possible pain) (NCT03638635)
Timeframe: Approximately every 6 hours through postoperative day 3 by 1 pm
| Intervention | units on a scale (Median) |
|---|---|
| Standard Bupivacaine | 3 |
| Bupivacaine Liposome | 3 |
Number of days from time of surgery until patient tolerates clear liquid diet (NCT03638635)
Timeframe: From time of surgery until first time patient tolerates clear liquids without nausea or vomiting. Assessed until date of discharge (usually up to 4 days after surgery).
| Intervention | days (Median) |
|---|---|
| Standard Bupivacaine | 0 |
| Bupivacaine Liposome | 0 |
Number of days from day of surgery until patient tolerates low fiber diet (NCT03638635)
Timeframe: From time of surgery until first time patient tolerates a low fiber diet without nausea or vomiting. Assessed until date of discharge (usually up to 4 days after surgery).
| Intervention | days (Median) |
|---|---|
| Standard Bupivacaine | 1.5 |
| Bupivacaine Liposome | 1 |
Number of days from day of surgery until patient mobilization (NCT03638635)
Timeframe: From time of surgery until time of first patient ambulation post op. Assessed until date of discharge (usually up to 4 days after surgery).
| Intervention | days (Median) |
|---|---|
| Standard Bupivacaine | 1 |
| Bupivacaine Liposome | 0.5 |
Number of days from time of surgery until return of bowel function (NCT03638635)
Timeframe: From time of surgery until first time patient passes gas or stool per rectum or into ostomy bag. Assessed until date of discharge (usually up to 4 days after surgery).
| Intervention | days (Median) |
|---|---|
| Standard Bupivacaine | 2 |
| Bupivacaine Liposome | 2 |
1 review available for bupivacaine and Colorectal Neoplasms
| Article | Year |
|---|---|
Effect of liposomal bupivacaine on opioid requirements and length of stay in colorectal enhanced recovery pathways: A systematic review and network meta-analysis.
Topics: Abdominal Muscles; Analgesics, Opioid; Anesthetics, Local; Bayes Theorem; Bupivacaine; Colorectal Ne | 2021 |
6 trials available for bupivacaine and Colorectal Neoplasms
| Article | Year |
|---|---|
Liposomal Bupivacaine Transversus Abdominis Plane Blocks in Laparoscopic Colorectal Resections: A Single-Institution Randomized Controlled Trial.
Topics: Abdominal Muscles; Adolescent; Adult; Aged; Aged, 80 and over; Bupivacaine; Colorectal Neoplasms; Hu | 2023 |
Efficacy and safety of intraperitoneal dexmedetomidine with bupivacaine in laparoscopic colorectal cancer surgery, a randomized trial.
Topics: Adult; Analgesics, Non-Narcotic; Anesthetics, Local; Bupivacaine; Colorectal Neoplasms; Dexmedetomid | 2015 |
Effects of preoperative ultrasound-guided transversus abdominis plane block on pain after laparoscopic surgery for colorectal cancer: a double-blind randomized controlled trial.
Topics: Abdominal Muscles; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anesthetics, Local; Bupivacai | 2017 |
Effects of preoperative ultrasound-guided transversus abdominis plane block on pain after laparoscopic surgery for colorectal cancer: a double-blind randomized controlled trial.
Topics: Abdominal Muscles; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anesthetics, Local; Bupivacai | 2017 |
Effects of preoperative ultrasound-guided transversus abdominis plane block on pain after laparoscopic surgery for colorectal cancer: a double-blind randomized controlled trial.
Topics: Abdominal Muscles; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anesthetics, Local; Bupivacai | 2017 |
Effects of preoperative ultrasound-guided transversus abdominis plane block on pain after laparoscopic surgery for colorectal cancer: a double-blind randomized controlled trial.
Topics: Abdominal Muscles; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anesthetics, Local; Bupivacai | 2017 |
Epidural blockade modifies perioperative glucose production without affecting protein catabolism.
Topics: Anesthesia, Epidural; Anesthesia, General; Blood Glucose; Blood Pressure; Bupivacaine; Colorectal Ne | 2002 |
Postoperative protein sparing with epidural analgesia and hypocaloric dextrose.
Topics: Aged; Amino Acids; Analgesia, Epidural; Analgesia, Patient-Controlled; Anesthesia, General; Anesthet | 2004 |
[Effect of continuous postoperative analgesia with peridural bupivacaine on intestinal motility following colorectal resection].
Topics: Aged; Analgesia, Epidural; Bupivacaine; Colectomy; Colorectal Neoplasms; Female; Gastrointestinal Mo | 1992 |
5 other studies available for bupivacaine and Colorectal Neoplasms
| Article | Year |
|---|---|
Effect of preoperative versus postoperative use of transversus abdominis plane block with plain 0.25 % bupivacaine on postoperative opioid use: a retrospective study.
Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Colorectal Neopl | 2021 |
Impact of Bupivacaine on malignant proliferation, apoptosis and autophagy of human colorectal cancer SW480 cells through regulating NF-κB signaling path.
Topics: Animals; Apoptosis; Autophagy; Bupivacaine; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplas | 2021 |
Epidural analgesia in open resection of colorectal cancer: is there a clinical benefit? a retrospective study on 1,470 patients.
Topics: Age Factors; Aged; Aged, 80 and over; Analgesia, Epidural; Analgesics, Opioid; Anastomotic Leak; Ane | 2011 |
[Effects of lumbar peridural anesthesia on tissue pO2 of the large intestine in man].
Topics: Aged; Anesthesia, Epidural; Bupivacaine; Colon; Colorectal Neoplasms; Female; Humans; Male; Middle A | 1995 |
Effect of epidural anesthesia on colorectal anastomosis: a tonometric assessment.
Topics: Adult; Aged; Anastomosis, Surgical; Anesthesia, Epidural; Bupivacaine; Colon; Colorectal Neoplasms; | 1997 |